Dr. Lilyana Amezcua, MD

Dr. Amezcua practices at Keck Hospital of USC in Los Angeles, California, part of University of Southern California.

Dr. Amezcua's NPI, 1306031240, was assigned on September 13, 2007. Dr. Amezcua graduated from Sidney Kimmel Medical College in 2002. Dr. Amezcua holds California license A86709.

Dr. Amezcua's primary practice is Keck Hospital of USC, at 1500 San Pablo Street, Los Angeles, CA 90033 in Los Angeles County. The practice phone is (323) 442-8656.

Dr. Amezcua's primary practice is Keck Hospital of USC in Los Angeles, California, part of University of Southern California. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Amezcua to 1 more group practice or clinic, 1 other site and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amezcua practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Amezcua's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Amezcua is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Amezcua's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists multiple sclerosis among the conditions Dr. Amezcua treats.

CMS data shows 138 Medicare services from Dr. Amezcua across 3 procedure codes in 2024, for 75 Medicare patients. Medicare paid $7,387 for them.

CMS counts 75 Medicare patients who saw Dr. Amezcua in 2024. The largest group is under 65, with 36 patients. 61% of them have arthritis, and 51% have high blood pressure. 48% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amezcua's median patient age at 50, with 71% women.

In 2024, Dr. Amezcua wrote 40 Medicare Part D claims. 30% of them were for generic drugs. CMS names the drug for 25 of them, across 2 drugs with 11 or more claims each, at $266,615 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

Dr. Amezcua accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Amezcua as offering telehealth.

Dmand AI links 22 papers to Dr. Amezcua, published from 2014 to 2025. 2017 was the busiest year, with 3. The most frequent topics are Multiple Sclerosis. Dr. Amezcua's most frequent co-authors are Mitzi Joi Williams, MD, Margaret Ellen Burnett, MD and Scott Douglas Newsome, DO.

Dmand AI links Dr. Amezcua to 4 clinical trials. Conditions studied include Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS and Multiple Sclerosis, Chronic Progressive. Open Payments lists research payments to Dr. Amezcua that name 1 trial.

CMS Open Payments shows 458 general payments to Dr. Amezcua from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 60% of the total. EMD Serono, Inc. paid the most, $100,728. It also lists 29 research payments totaling $21,675 from 2018 to 2025, naming 1 clinical trial.

Dr. Amezcua graduated from Sidney Kimmel Medical College in 2002. Dr. Amezcua is a member of AAN.

Dr. Amezcua is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.